AR097886A1 - Agente terapéutico para el asma grave, método, uso - Google Patents

Agente terapéutico para el asma grave, método, uso

Info

Publication number
AR097886A1
AR097886A1 ARP140103660A ARP140103660A AR097886A1 AR 097886 A1 AR097886 A1 AR 097886A1 AR P140103660 A ARP140103660 A AR P140103660A AR P140103660 A ARP140103660 A AR P140103660A AR 097886 A1 AR097886 A1 AR 097886A1
Authority
AR
Argentina
Prior art keywords
therapeutic agent
serious asthma
asthma
serious
tetomilast
Prior art date
Application number
ARP140103660A
Other languages
English (en)
Inventor
Nagamoto Hisashi
Kimura Naoji
Kotosai Kounori
Karasutani Keiko
Kanda Norio
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR097886A1 publication Critical patent/AR097886A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un agente terapéutico para el asma grave caracterizado porque comprende tetomilast o una de sus sales farmacéuticamente aceptable.
ARP140103660A 2013-10-03 2014-10-02 Agente terapéutico para el asma grave, método, uso AR097886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013208153 2013-10-03

Publications (1)

Publication Number Publication Date
AR097886A1 true AR097886A1 (es) 2016-04-20

Family

ID=52778832

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103660A AR097886A1 (es) 2013-10-03 2014-10-02 Agente terapéutico para el asma grave, método, uso

Country Status (3)

Country Link
AR (1) AR097886A1 (es)
TW (1) TW201542207A (es)
WO (1) WO2015050249A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005210084B2 (en) * 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
PL1891974T3 (pl) * 2004-05-31 2010-12-31 Almirall Sa Kombinacje zawierające środki przeciwmuskarynowe i inhibitory PDE4
TW200815054A (en) * 2006-06-19 2008-04-01 Otsuka Pharma Co Ltd Methods of using a thiazole derivative

Also Published As

Publication number Publication date
TW201542207A (zh) 2015-11-16
WO2015050249A1 (ja) 2015-04-09

Similar Documents

Publication Publication Date Title
DK3706796T3 (da) Eksosomerer som RNA terapeutikske midler
BR112017023853A2 (pt) composições de nanopartícula para terapia sustentada.
DK3331864T3 (da) 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse
DK3328849T5 (da) 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
JP2016028092A5 (es)
DK3587417T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
JP2016065085A5 (es)
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
EP3154594A4 (en) Fap-activated therapeutic agents, and uses related thereto
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
CL2014003472A1 (es) Pro-farmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)acrilamida; composicion farmaceutica que los comprende; y su uso para tratar una infeccion bacteriana.
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
DK3104838T3 (da) Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf
PE20151435A1 (es) Laquinimod para reducir el dano talamico en la esclerosis multiple
EP3371201A4 (en) Conjugated antisense compounds for use in therapy
EP3322444A4 (en) A TUMOR THERAPEUTIC AGENT COMPRISING AN IDO INHIBITOR ADMINISTERED IN ASSOCIATION WITH ANTIBODY
EA201890212A1 (ru) Новое применение сульфата декстрана
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
ES2611776T3 (es) Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos
DK3706710T3 (da) Formuleringer med forlænget frigivelse til intraartikulære anvendelser
DK3245643T3 (da) Stand-up display, navnlig stand-up display figur
JP2015521279A5 (es)
PL3250181T3 (pl) Formulacja farmaceutyczna na bazie minoksydylu do stosowania miejscowego i jej zestaw

Legal Events

Date Code Title Description
FB Suspension of granting procedure